These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7986719

  • 61. Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
    Bertina RM, van der Linden IK.
    Thromb Haemost; 1982 Apr 30; 47(2):136-40. PubMed ID: 7101232
    [Abstract] [Full Text] [Related]

  • 62. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
    Barco S, Whitney Cheung Y, Coppens M, Hutten BA, Meijers JC, Middeldorp S.
    Br J Haematol; 2016 Jan 30; 172(2):255-61. PubMed ID: 26488126
    [Abstract] [Full Text] [Related]

  • 63. Recombinant factor VIIa does not induce hypercoagulability in vitro.
    Gallistl S, Cvirn G, Muntean W.
    Thromb Haemost; 1999 Feb 30; 81(2):245-9. PubMed ID: 10064000
    [Abstract] [Full Text] [Related]

  • 64. The preparation and clinical use of a new concentrate containing factor IX, prothrombin and factor X and of a separate concentrate containing factor VII.
    Dike GW, Bidwell E, Rizza CR.
    Br J Haematol; 1972 Apr 30; 22(4):469-90. PubMed ID: 4112845
    [No Abstract] [Full Text] [Related]

  • 65. High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential.
    Limentani SA, Gowell KP, Deitcher SR.
    Acta Haematol; 1995 Apr 30; 94 Suppl 1():12-7. PubMed ID: 7571989
    [Abstract] [Full Text] [Related]

  • 66. Disappearance of inhibitor to factor IX in a patient with severe haemophilia B and immunological characterization of the inhibitor.
    Ohkubo Y, Takahashi Y, Sugimoto M, Nishino M, Nishimura T, Yoshioka A, Fukui H.
    Clin Lab Haematol; 1988 Apr 30; 10(2):177-85. PubMed ID: 2843318
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V, Jouppila A, Lassila R.
    Int J Lab Hematol; 2017 Aug 30; 39(4):359-368. PubMed ID: 28406575
    [Abstract] [Full Text] [Related]

  • 77. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K, Hirose S, Taguchi H, Miyoshi I.
    Rinsho Ketsueki; 1985 Jun 30; 26(6):980-4. PubMed ID: 3877825
    [No Abstract] [Full Text] [Related]

  • 78. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP, Klessen C, Jablonowski C, Meerbach W, Dornheim G.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984 Jun 30; 111(5):645-61. PubMed ID: 6083940
    [Abstract] [Full Text] [Related]

  • 79. Comparison between two concentrates with factor VIII inhibitor bypassing activity.
    Vinazzer H.
    Thromb Res; 1982 Apr 01; 26(1):21-9. PubMed ID: 6980497
    [Abstract] [Full Text] [Related]

  • 80. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards.
    Gray E, Pickering W, Hockley J, Rigsby P, Weinstein M, Terao E, Buchheit KH.
    Pharmeuropa Bio; 2008 Dec 01; 2008(1):19-30. PubMed ID: 19220978
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.